The chart below shows the treatment plan for the participants. The doses of
treatment were measured in milligrams, also known as “mg”.
Group 1 Group 2 Group 3 Group 4
26 19 12 12
participants participants participants participants
Had not Had not
Already had Already had
already had already had
treatment treatment
treatment treatment
• acalabrutinib: as a • acalabrutinib: as a • acalabrutinib: as a
capsule by mouth capsule by mouth capsule by mouth
• obinutuzumab: • rituximab: through a • obinutuzumab:
through a needle into needle into a vein through a needle into
a vein • venetoclax: as a a vein
tablet by mouth • venetoclax: as a
tablet by mouth
• acalabrutinib: twice • acalabrutinib: twice • acalabrutinib: twice
daily daily daily
• obinutuzumab: four • rituximab: once a • obinutuzumab: four
times in the second week for 4 weeks in times in the second
cycle, then 1 time at the second cycle, cycle, then 1 time at
the start of each cycle then once at the start the start of each cycle
for 5 cycles of each cycle until the for 5 cycles
7th cycle • venetoclax: once a
• venetoclax: once a day in the third cycle
day in the third cycle starting at a very low
starting at a very low dose. This slowly got
dose. This slowly got higher to 400 mg a
higher to 400 mg a day. This was then
day. This was then taken once a day
taken once a day until the end of
until the end of cycle 15
cycle 15
Participants stayed in the trial until their cancer got worse, or they
decided to leave the trial. The participants were able to stay in the trial
for as long as the doctors felt the trial treatment was helping them.
5 | Clinical Trial Results